Tumor Suppressor Candidate 3: A Novel Grading Tool and Predictor of Clinical Malignancy in Human Gliomas

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Mar 21

PMID 29556302

Citations 4

Authors

Jing Yuan

Xinshuang Yu

Aihua Wang

Yan Li

Fengjun Liu

Yao Wang

Shanmei Sun

Xiuyang Bing

Yiming Liu

Juan Du

Affiliations

Soon will be listed here.

Abstract

For several years, the cause of autosomal recessive mental retardation has been attributed to the deletion or mutation of a gene named tumor suppressor candidate 3 (TUSC3). Previous research has identified that TUSC3 is a potential tumor suppressor gene in oral epidermoid carcinoma, lung cancer and esophageal cancer. However, to the best of our knowledge, no previously published data has existed on the expression of TUSC3 in gliomas. The present study focused on the expression of TUSC3 in brain gliomas. Additionally, the present study sought to identify he association between TUSC3 expression and the typical clinical and pathological disease manifestations of gliomas. TUSC3 levels were evaluated using a western blot assay and immunohistochemistry on tissue microarray slides. Results indicated a significant decrease in TUSC3 expression in glioma tissues compared with the normal adjacent tissues. Furthermore, TUSC3 expression and World Health Organization grade demonstrated an inverse association in patients with glioma. This revealed that lower levels of TUSC3 in gliomas may be associated with a poorly-differentiated (high grade) tumor and thus a higher malignancy. Through the combination of the results of the present study and future research projects, TUSC3 may be a novel grading tool that assists with evaluating tumor malignancy and consequently a more active therapeutic regimen may be used in patients with glioma.

Citing Articles

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.

Wu Q, Berglund A, Macaulay R, Etame A Int J Mol Sci. 2023; 24(20).

PMID: 37894860 PMC: 10606804. DOI: 10.3390/ijms242015179.

Genome-Wide Identification of Cis-acting Expression QTLs in Large Yellow Croaker.

Jiang D, Li W, Wang Z, Fang M Mar Biotechnol (NY). 2021; 23(2):225-232.

PMID: 33507423 DOI: 10.1007/s10126-020-10017-0.

Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3.

Kong L, Sun Y, Chen M, Dai Y, Liu Z Exp Ther Med. 2020; 20(5):9.

PMID: 32934674 PMC: 7471862. DOI: 10.3892/etm.2020.9137.

Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Granados-Soler J, Bornemann-Kolatzki K, Beck J, Brenig B, Schutz E, Betz D Sci Rep. 2020; 10(1):1003.

PMID: 31969654 PMC: 6976565. DOI: 10.1038/s41598-020-57942-7.

References

Mohorko E, Glockshuber R, Aebi M . Oligosaccharyltransferase: the central enzyme of N-linked protein glycosylation. J Inherit Metab Dis. 2011; 34(4):869-78. DOI: 10.1007/s10545-011-9337-1. View

Horak P, Tomasich E, Vanhara P, Kratochvilova K, Anees M, Marhold M . TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. Sci Rep. 2014; 4:3739. PMC: 3894551. DOI: 10.1038/srep03739. View

Walsh K, Ohgaki H, Wrensch M . Epidemiology. Handb Clin Neurol. 2016; 134:3-18. DOI: 10.1016/B978-0-12-802997-8.00001-3. View

Khan M, Rafiq M, Noor A, Ali N, Ali G, Vincent J . A novel deletion mutation in the TUSC3 gene in a consanguineous Pakistani family with autosomal recessive nonsyndromic intellectual disability. BMC Med Genet. 2011; 12:56. PMC: 3096909. DOI: 10.1186/1471-2350-12-56. View

Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak T . The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell. 2010; 143(5):711-24. DOI: 10.1016/j.cell.2010.10.010. View

Rizzo D, Ruggiero A, Martini M, Rizzo V, Maurizi P, Riccardi R . Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int. 2015; 2015:215135. PMC: 4584033. DOI: 10.1155/2015/215135. View

Jamaluddin M, Bailey U, Tan N, Stark A, Schulz B . Polypeptide binding specificities of Saccharomyces cerevisiae oligosaccharyltransferase accessory proteins Ost3p and Ost6p. Protein Sci. 2011; 20(5):849-55. PMC: 3125869. DOI: 10.1002/pro.610. View

Bashyam M, Bair R, Kim Y, Wang P, Hernandez-Boussard T, Karikari C . Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005; 7(6):556-62. PMC: 1501288. DOI: 10.1593/neo.04586. View

Reifenberger G, Wirsching H, Knobbe-Thomsen C, Weller M . Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2016; 14(7):434-452. DOI: 10.1038/nrclinonc.2016.204. View

10.

MacGrogan D, Levy A, Bova G, Isaacs W, Bookstein R . Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996; 35(1):55-65. DOI: 10.1006/geno.1996.0322. View

11.

Das R, Heath E . Dolichyldiphosphoryloligosaccharide--protein oligosaccharyltransferase; solubilization, purification, and properties. Proc Natl Acad Sci U S A. 1980; 77(7):3811-5. PMC: 349716. DOI: 10.1073/pnas.77.7.3811. View

12.

Vanhara P, Horak P, Pils D, Anees M, Petz M, Gregor W . Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. Int J Oncol. 2013; 42(4):1383-9. DOI: 10.3892/ijo.2013.1824. View

13.

Kelleher D, Karaoglu D, Mandon E, Gilmore R . Oligosaccharyltransferase isoforms that contain different catalytic STT3 subunits have distinct enzymatic properties. Mol Cell. 2003; 12(1):101-11. DOI: 10.1016/s1097-2765(03)00243-0. View

14.

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

15.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

16.

Birnbaum D, Adelaide J, Mamessier E, Finetti P, Lagarde A, Monges G . Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer. 2011; 50(6):456-65. DOI: 10.1002/gcc.20870. View

17.

Zhou H, Clapham D . Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. Proc Natl Acad Sci U S A. 2009; 106(37):15750-5. PMC: 2732712. DOI: 10.1073/pnas.0908332106. View

18.

Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A . Methylation status of TUSC3 is a prognostic factor in ovarian cancer. Cancer. 2012; 119(5):946-54. DOI: 10.1002/cncr.27850. View

19.

Guervos M, Alvarez Marcos C, Hermsen M, Sampedro Nuno A, Suarez C, Llorente J . Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas. Cell Oncol. 2007; 29(4):327-34. PMC: 4618212. DOI: 10.1155/2007/635962. View

20.

Ribeiro I, Marques F, Caramelo F, Pereira J, Patricio M, Prazeres H . Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management. Cell Oncol (Dordr). 2013; 37(1):29-39. DOI: 10.1007/s13402-013-0161-5. View